SASaeed Alghamdi

Saeed Alghamdi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Saeed Alghamdi has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Mohammed A. Aldriweesh

    King Saud Bin Abdulaziz University for Health Sciences, College of Medicine, Riyadh, Saudi Arabia

    3 shared publications
  • Mohammed Khalid Bukhari

    Neurology, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU

    2 shared publications
  • Seraj Makkawi

    College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia

    2 shared publications
  • Abdulaziz A. Aldbas

    Department of Neurology, King Abdullah International Medical Research Center, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia, P.O. Box 22490 11426

    1 shared publication
  • Ali M Al Khathaami

    King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

    1 shared publication
  • Ali M. Al Khathaami

    Division of Neurology, Department of Medicine, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia

    1 shared publication

Latest Publications

  • Open Access

    The Role of the Discharge Planning Team on the Length of Hospital Stay and Readmission in Patients with Neurological Conditions: A Single-Center Retrospective Study

    by Anmar Fatani, Sarah Alzebaidi, Himyan Kamel Alghaythee, Suzan Alharbi, Mohammed Hisham Bogari, Hassan K. Salamatullah, Saeed Alghamdi, Seraj Makkawi

    Background: Emerging evidence highlights the critical role of discharge planning teams in enhancing patient care. However, there is lack of data regarding how the implementation of a discharge planning system influences the length of stay (LOS) in hospital and readmission rates among patients with neurological diseases. We conducted a retrospective analysis to examine the effects of discharge planning application on the LOS and readmission rates for patients admitted under the neurology service in Saudi Arabia. Methods: This is a retrospective study conducted at King Abdulaziz Medical City—Western region of Saudi Arabia. We included all patients admitted and discharged under the neurology service between January 2018 and December 2019. The included patients who were divided into the 2018 group (not exposed to discharge planner) and the 2019 group (exposed to discharge planner). The primary endpoints were the LOS and readmission rates. Results: The study included 856 patients (436 allocated to the 2019 group and 420 allocated to the 2018 group). There was no difference between the two groups in the LOS after adjusting confounding factors (β = −0.58, 95% CI [−2.79, 1.61], p = 0.60). However, the 2019 group were more likely to be discharged within three days compared to the 2018 group (41% vs. 26%, p < 0.005). Our analysis showed that patients in the 2019 group were less likely to be readmitted compared to the 2018 group (adjusted odds ratio = 0.70, 95% CI [0.49–0.99], p = 0.0442). Conclusions: Implementation of a discharge planning team was associated with higher early discharge rates and lower hospital readmissions, suggesting potential benefits for healthcare resource utilization in neurological services.


  • Clinical characteristics, Risk factors, and outcomes of Posterior circulation stroke: A retrospective study between younger and older adults in Saudi Arabia

    by Mohammed A. Aldriweesh, Abdulaziz A. Aldbas, Osama Khojah, Faisal Yonbawi, Edi A. Shafaay, Ghadeer L. Aljahdali, Mohammed Khalid Bukhari, Yousef Qari, Manar M. Almuntashri, Aljoharah A. Alshaikh, et al.


  • Open Access

    Anti-mGluR1 encephalitis: Case illustration and systematic review

    by Osama Khojah, Seraj Makkawi, Saeed Alghamdi

    Background: The literature for immune-mediated neurological disorders is evolving like no other field of neurological illnesses. Many new antibodies or disorders have been described in the last decade. The cerebellum is a brain structure susceptible to these immune-mediated pathologies, and anti-metabotropic glutamate receptor 1 (mGluR1) antibody has a predilection to the cerebellar tissue. Anti-mGluR1 encephalitis is a rare autoimmune disease affecting the central and peripheral nervous systems, triggering an acute or subacute cerebellar syndrome with varying degrees of severity. Anti-mGluR1 encephalitis is a rare autoimmune disease affecting the central nervous system. We aimed to systematically review reported cases of anti-mGluR1 encephalitis and summarize their clinical presentation, management, outcomes, and case reports.Methods: A search of the PubMed and Google Scholar databases was conducted and included all cases of anti-mGluR1 encephalitis published in English before October 1, 2022. A comprehensive systematic review was conducted using “metabotropic glutamate receptor type 1,” “mGluR1,” autoantibodies,” “autoantibodies,” “autoimmunity,” and “antibody” as keywords. The risk of bias assessment of the evidence was performed using appropriate tools. The qualitative variables were presented as frequency and percentage.Results: Including our case, 36 cases of anti-mGluR1 encephalitis (19 males, median age 52.5 years, 11.1% pediatric cases) have been reported. The most common clinical manifestations are ataxia, dysarthria, and nystagmus. Initial imaging was normal in 44.4% of patients; however, 75% of patients showed abnormality later in the disease course. The first-line therapy options include glucocorticoids, intravenous immunoglobulin, and plasma exchange. Rituximab is the most commonly used second-line treatment. Complete remission was achieved in only 22.2% of patients, and 61.8% were disabled by the end of their course.Conclusion: Anti-mGluR1 encephalitis manifests as symptoms of cerebellar pathology. Although the natural history has not been completely elucidated, early diagnosis with prompt initiation of immunotherapy could be imperative. Any patient suspected to have autoimmune cerebellitis should be tested for the presence of anti-mGluR1 antibody in the serum and cerebrospinal fluid. Escalation to an aggressive therapy approach should be applied in cases that do not respond to first-line therapies, and extended follow-up durations are required in all cases.


  • Open Access

    Ischemic Stroke Secondary to Dynamic Vertebral Artery Stenosis: Case Report and Review of the Literature

    by Mohammed K. Bukhari, Saeed A Alghamdi

    Ischemic stroke secondary to dynamic vertebral artery stenosis or occlusion, also known as “bow hunter's syndrome,” is a rare stroke mechanism. We report a case of a 24-year-old man with multiple hereditary exostosis (MHE) diagnosed at childhood. His first presentation to a neurologist was due to neck pain and clinical syndrome suggestive of ischemia in the vertebrobasilar territory. A therapeutic occlusion was done successfully without complication. The patient was discharged two days later on aspirin alone. In follow up one year later he continued to be symptom free. Moreover, this stroke mechanism has been reported extensively in the literature in isolation or secondary to many underlying diseases. In total, there are 168 cases reported in the published English literature, in either case reports or small series. In this review, we found that by far, vertebral artery occlusion at the atlanto-axial (C1-2) level dominated most reported cases. The most frequent presentation that led to further investigation was syncope or pre-syncope provoked by head rotation to one side. To our knowledge, there is no previous report of any stroke syndrome related to MHE before our case. In this paper, we report the first case secondary to MHE and review the literature up to date since the first reported case in 1952.


  • Open Access

    Stroke Seasonality and Weather Association in a Middle East Country: A Single Tertiary Center Experience

    by Saeed A. M. Alghamdi, Mohammed A. Aldriweesh, Bayan A. Al Bdah, Muath A. Alhasson, Sultan A. Alsaif, Waleed A. Alluhidan, Faisal M. Almutairi, Naser Alotaibi, Ali M. Al Khathaami

    Background: Stroke is a medical condition that leads to major disability and mortality worldwide. Some evidence suggests that weather and seasonal variations could have an impact on stroke incidence and outcome. However, the current evidence is inconclusive. Therefore, this study examines the seasonal variations and meteorological influences on stroke incidence and outcome in the largest city in Saudi Arabia.Methods: From February 2016 to July 2019, we retrospectively reviewed data from all patients with acute ischemic (AIS) or hemorrhagic stroke (HS) admitted to the stroke unit in a tertiary academic center in Saudi Arabia. The corresponding daily meteorological data were obtained for the same period. We considered the months from November to March as the cold season and April to October as the hot season.Results: The final cohort included 1,271 stroke patients; 60.89% (n = 774) cases occurred in the hot season, while 39.1% (n = 497) in the cold season. Males accounted for 69.6% (n = 884) of the cases. The proportion of ischemic stroke was 83.2% [hot season 83.9% (n = 649) vs. cold season 82.3% (n = 409)]. We found no statistically significant difference between seasons (hot or cold) in stroke incidence, severity [National Institutes of Health Stroke Scale (NIHSS)], hospital course (pneumonia, thromboembolism, intensive care stay, or length of stay), or outcome [modified Rankin scale (mRS) on discharge and death].Conclusions: In Riyadh, Saudi Arabia, our study found no impact of weather or seasonal variations on stroke incidence, hospital course, or outcomes. However, our findings warrant further research in different country regions.


  • Anterior circulation large vessel occlusion stroke in Saudi Arabia: Prevalence, predictors, and outcome

    by Ali M Al Khathaami, Mohammed A Aldriweesh, Bayan A Al Bdah, Muath A Alhasson, Sultan A Alsaif, Waleed A Alluhidan, Faisal M Almutairi, Mohammed A Alskaini, Nasser Alotaibi, Saeed A M Alghamdi


  • Open Access

    Stroke management pathway during COVID-19 pandemic scientific statement by the Saudi Stroke Society

    by Saeed S. Alzahrani, Farah K. Aleisa, Jamilah A. Alghalbi, Nouran Y. Taher, Saeed A. Alqahtani, Nabat A. Majrashi, Areej A. Alasseri, Saeed A. Alghamdi


  • Fatal serotonin syndrome in a patient with Marchiafava–Bignami disease: Combined neurological and psychiatric emergency

    by Saeed Alghamdi, Yehya Seddeq, Hussein Algahtani, Bader Shirah

    Marchiafava-Bignami disease (MBD) is a rare fatal neurological disorder characterized by demyelination, primary degeneration, and necrosis of the corpus callosum. Although MBD is mostly associated with chronic alcohol consumption and malnutrition, it has been reported in non-alcoholic patients. Serotonin syndrome is a rare but potentially fatal side effect of antidepressants that results from overstimulation of both central and peripheral serotonergic receptors. In this report, we present a case with fatal serotonin syndrome happening in a non-alcoholic patient with the chronic form of MBD. To our knowledge, this case is the first report of fatal serotonin syndrome due to citalopram in an MBD patient. The present report may indicate that citalopram and other SSRIs should not be used in patients with MBD. Our case is also among few reported cases in the literature where no cause was identified in a patient with no previous history of alcohol intake.